Phase I study of the cisplatin analogue 1,1-diamminomethylcyclohexane sulfatoplatinum (TNO-6) (NSC 311056).

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Phase I study of the cisplatin analogue 1,1-diamminomethylcyclohexane sulfatoplatinum (TNO-6) (NSC 311056). / Sørensen, J B; Groth, S; Hansen, S W; Nissen, Mogens Holst; Rørth, M; Hansen, H H.

In: Cancer Chemotherapy and Pharmacology, Vol. 15, No. 2, 1985, p. 97-100.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Sørensen, JB, Groth, S, Hansen, SW, Nissen, MH, Rørth, M & Hansen, HH 1985, 'Phase I study of the cisplatin analogue 1,1-diamminomethylcyclohexane sulfatoplatinum (TNO-6) (NSC 311056).', Cancer Chemotherapy and Pharmacology, vol. 15, no. 2, pp. 97-100.

APA

Sørensen, J. B., Groth, S., Hansen, S. W., Nissen, M. H., Rørth, M., & Hansen, H. H. (1985). Phase I study of the cisplatin analogue 1,1-diamminomethylcyclohexane sulfatoplatinum (TNO-6) (NSC 311056). Cancer Chemotherapy and Pharmacology, 15(2), 97-100.

Vancouver

Sørensen JB, Groth S, Hansen SW, Nissen MH, Rørth M, Hansen HH. Phase I study of the cisplatin analogue 1,1-diamminomethylcyclohexane sulfatoplatinum (TNO-6) (NSC 311056). Cancer Chemotherapy and Pharmacology. 1985;15(2):97-100.

Author

Sørensen, J B ; Groth, S ; Hansen, S W ; Nissen, Mogens Holst ; Rørth, M ; Hansen, H H. / Phase I study of the cisplatin analogue 1,1-diamminomethylcyclohexane sulfatoplatinum (TNO-6) (NSC 311056). In: Cancer Chemotherapy and Pharmacology. 1985 ; Vol. 15, No. 2. pp. 97-100.

Bibtex

@article{613c6050ba3611ddae57000ea68e967b,
title = "Phase I study of the cisplatin analogue 1,1-diamminomethylcyclohexane sulfatoplatinum (TNO-6) (NSC 311056).",
abstract = "The cisplatin derivative TNO-6 was evaluated for clinical toxicity in a phase I trial. TNO-6 was given daily for 5 days every 3 weeks as a 30-min IV infusion without hydration. In all, 39 patients with advanced cancer were treated at doses of 2.5-9.0 mg/m2. No dose-limiting nephrotoxicity occurred, but evidence of mild, reversible tubular damage was found. Dose-limiting toxicity was hematologic with both thrombopenia and leukocytopenia, which with high dose levels reached WHO grade 4. Hematologic toxicity was most pronounced for pretreated patients. No antitumor activity was seen. The recommended dose for phase II trials will be 9.0 mg/m2 for previously untreated and 8.0 mg/m2 for pretreated patients.",
author = "S{\o}rensen, {J B} and S Groth and Hansen, {S W} and Nissen, {Mogens Holst} and M R{\o}rth and Hansen, {H H}",
note = "Keywords: Adult; Aged; Drug Evaluation; Female; Humans; Iodohippuric Acid; Kidney Tubules; Leukopenia; Male; Middle Aged; Nausea; Neoplasms; Organoplatinum Compounds; Pentetic Acid; Proteinuria; Technetium; Technetium Tc 99m Pentetate; Thrombocytopenia",
year = "1985",
language = "English",
volume = "15",
pages = "97--100",
journal = "Cancer Chemotherapy and Pharmacology, Supplement",
issn = "0943-9404",
publisher = "Springer",
number = "2",

}

RIS

TY - JOUR

T1 - Phase I study of the cisplatin analogue 1,1-diamminomethylcyclohexane sulfatoplatinum (TNO-6) (NSC 311056).

AU - Sørensen, J B

AU - Groth, S

AU - Hansen, S W

AU - Nissen, Mogens Holst

AU - Rørth, M

AU - Hansen, H H

N1 - Keywords: Adult; Aged; Drug Evaluation; Female; Humans; Iodohippuric Acid; Kidney Tubules; Leukopenia; Male; Middle Aged; Nausea; Neoplasms; Organoplatinum Compounds; Pentetic Acid; Proteinuria; Technetium; Technetium Tc 99m Pentetate; Thrombocytopenia

PY - 1985

Y1 - 1985

N2 - The cisplatin derivative TNO-6 was evaluated for clinical toxicity in a phase I trial. TNO-6 was given daily for 5 days every 3 weeks as a 30-min IV infusion without hydration. In all, 39 patients with advanced cancer were treated at doses of 2.5-9.0 mg/m2. No dose-limiting nephrotoxicity occurred, but evidence of mild, reversible tubular damage was found. Dose-limiting toxicity was hematologic with both thrombopenia and leukocytopenia, which with high dose levels reached WHO grade 4. Hematologic toxicity was most pronounced for pretreated patients. No antitumor activity was seen. The recommended dose for phase II trials will be 9.0 mg/m2 for previously untreated and 8.0 mg/m2 for pretreated patients.

AB - The cisplatin derivative TNO-6 was evaluated for clinical toxicity in a phase I trial. TNO-6 was given daily for 5 days every 3 weeks as a 30-min IV infusion without hydration. In all, 39 patients with advanced cancer were treated at doses of 2.5-9.0 mg/m2. No dose-limiting nephrotoxicity occurred, but evidence of mild, reversible tubular damage was found. Dose-limiting toxicity was hematologic with both thrombopenia and leukocytopenia, which with high dose levels reached WHO grade 4. Hematologic toxicity was most pronounced for pretreated patients. No antitumor activity was seen. The recommended dose for phase II trials will be 9.0 mg/m2 for previously untreated and 8.0 mg/m2 for pretreated patients.

M3 - Journal article

C2 - 3893780

VL - 15

SP - 97

EP - 100

JO - Cancer Chemotherapy and Pharmacology, Supplement

JF - Cancer Chemotherapy and Pharmacology, Supplement

SN - 0943-9404

IS - 2

ER -

ID: 8746841